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Abstract 
 
Countless statistical methods have been described for the analysis of DNA microarrays, 
and each yields distinct results. This raises the question whether DNA microarrays are 
robust diagnostic tools.  
 
In order to address this issue, we compared five formally similar statistical tests for gene 
selection on a single data set derived from acute leukemia patients. Inter-test agreement 
of gene selection, of sample classification and with standard clinical diagnosis was 
calculated using Cohen’s κ - score.  
 
The inter-test agreement scores were 0.15 < κ < 0.68 for gene selection, and 0.60 < κ < 
0.89 for sample classification. Comparison to the clinical diagnosis showed agreement 
scores of 0.58< κ < 0.88. ‘Marginal imbalance’ explains the low κ-scores at the level of 
gene selection. At the levels of sample classification and agreement with clinical 
diagnosis, κ-scores can be considered “substantial” to “excellent”. 
  
For diagnostic purposes, the inter-test agreement of DNA microarrays is equivalent to 
that of experienced clinicians, as reported in the literature. The technique can thus be 
considered a useful and robust addendum to the available diagnostic tools. 
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Introduction 
The most promising clinical potential for DNA microarrays lies in sample 
classification for diagnostic purposes1-4. More accurate diagnosis may allow more precise 
prognosis, and thus, determine therapeutic decisions.  
It has become clear that gene clusters (“signatures”), rather than the expression of 
individual genes, yield higher information contents. The ultimate aim is to move from 
signatures to models, that is, to analyze the data, integrate the information, and thus, gain 
knowledge1.  
The information contained in the expression data is made available through a 
sequence of statistical analyses, which are not yet standardized. Most reports on DNA 
microarray data feature a very unique methodology. This makes comparison of results 
very difficult5.  
When assessing the clinical usefulness of a new diagnostic technique, several 
points must be taken into consideration. One is the consistency or robustness of the 
clinical interpretation of the technology, i.e. a positive answer to the question whether 
different observers will come to the same conclusion by using this diagnostic technique. 
Another is the diagnostic gain, i.e. a positive answer to the question whether the new 
technology allows better (faster, more reliable, cheaper) diagnosis than the currently used 
best standard technology. 
The present study formally addresses the first of these questions. More precisely, 
we ask: if one and the same set of microarray data is analyzed using different statistical 
tests at the same analytic step, will the final conclusions remain the same?  
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 In addition, we discuss indirect hints on the potential diagnostic gain from the use 
of DNA microarrays for cancer classification. 
 
Results 
The comparison of inter- test agreement for the selection of genes produced low 
kappa scores: only one of the ten comparisons yielded “substantial” agreement, while 
three each gave “slight”, “fair” and “moderate” agreement (Table 1)6,7. If the five gene 
sets are then used to classify the remaining samples for diagnosis, the inter-test agreement 
scores are far higher (Table 2). All kappa scores show “substantial” or “almost perfect” 
agreement.  
In order to compare agreement with the standard clinical diagnosis of each sample 
given by Golub8, we calculated kappa scores for each statistical method. In this 
comparison, the tests showed κ - scores from 0.58 to 0.88 (Table 3). One each would thus 
be considered to show “moderate” or “substantial” agreement with the clinical diagnosis, 
while the three others had “almost perfect” agreement”6,7.  
 
Discussion 
 The stepwise calculation of κ-scores showed low average κ-scores, indicative of 
only “fair” agreement at the gene selection stage but “substantial” agreement for sample 
classification, and for agreement with the clinical diagnosis. This apparent discrepancy 
can be explained by the large “marginal imbalance” between selected genes (n=50) and 
unselected genes (n=6095)9,10 at the selection step, and the good balance at the 
classification step.  
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From a purely statistical point of view, the good inter-test agreement is already 
reassuring. Dudoit, however, pointed out that statistical significance is not the same as 
biological significance in the interpretation of DNA microarray expression profiles11. We 
have been able to demonstrate that, using this same data set with the intention to identify 
biological pathways, the same statistical tests lead to a much less robust knowledge gain12. 
The observation of diagnostic robustness made here becomes thus much less trivial than 
the use of formally similar statistical tests might suggest.   
When using microarrays for diagnostic purposes, they should be expected to agree 
as much or better than experienced clinicians would agree on the diagnosis.  
From a clinical perspective, the diagnostic agreement with κ - scores from 0.58 to 
0.88 (Table 3) is very competitive. McCarthy’s recent study of 462 cases of leukemia 
showed kappa scores between 0.58 and 0.94 using histomorphology as diagnostic 
criterion13. Of the 26 inter- tester comparisons reported in that study, 12 achieved a kappa 
score of 0.8 or above, which is commonly regarded as “almost perfect” inter- tester 
agreement6,7.  
The results presented here support the hope14 that microarrays with large gene sets 
may yield knowledge from small sample numbers and thus facilitate clinical diagnosis.  
Previous studies observed that the same data set, depending on which statistical 
method the researcher chooses to make use of, may provide considerably different 
“knowledge” gain. Suarez- Farinas’ re- analysis of raw data from three different 
microarray experiments on the same tissue, now using the same statistical methods 
throughout, resulted in much more coherent conclusions than the previous comparison of 
the reported results had obtained5. In other words, a standardized approach to analyzing 
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distinct raw data sets makes comparisons across technical platforms possible, while re- 
analysis of the same distinct data sets with different approaches increases the confusion 
rather than the knowledge gain. Using a standardized approach to handling the raw data 
derived from DNA expression microarrays has thus emerged as a key issue in the 
biological interpretation of the statistical findings, whether at the individual study level or 
for meta- analysis of such studies15.  
As the kappa scores reported here are from a different data set than those 
described by McCarthy13, the second question (“what is the diagnostic gain?”) asked in 
the introduction section cannot be answered directly. At present, DNA microarrays are 
still slower to give a diagnosis and more costly, but both these obstacles may soon be 
overcome. If microarrays give information that allows more precise classification than 
the standard, histomorphological approach with regards to prognostic class or for the 
choice of therapeutic strategy, then microarrays will introduce a qualitative gain that may 
outweigh economical considerations. Miller et al. may have achieved this goal16 by 
identifying a gene expression signature that distinguishes p53-mutant and wild-type 
tumors of different histologies and outperforms sequence-based assessments of p53 status 
in predicting prognosis and therapeutic response.  
Technical problems concerning the reproducibility of findings even on the same 
platform have sparked research that resulted in more reliable data acquisition and analysis 
methods. By today, much information is gained from studies that use cross- platform 
approaches and have advanced from the lab bench close to the bedside7,17,18. In particular, 
Suarez- Farinas provided evidence that a normalized approach to data analysis will result 
in higher coherence of results5, while Michiels et al have drawn attention to the need to 
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critically appraise this information before eventually accepting the newly gained 
knowledge19.  
The results presented here show that microarray analysis has reached a level of 
intertest agreement similar to that seen in experienced clinicians. This observation should 
encourage clinicians to consider using microarray analysis as part of diagnostic 
procedures.  
 
Methods 
We assessed the inter- test agreement as described by Cohen’s κ-score between 
five statistical tests 8,20-23 used in the analysis of DNA microarray expression data24. The 
data set analyzed was from the well characterized study on acute leukemia by Golub et al. 
which has a detailed methodology section that allows stepwise replication of the analysis8. 
The authors have updated their methodology and allow download from a dedicated 
website25. Appendix Part A gives a brief explanation of the five tests used, of Cohen’s 
kappa score, and of the original dataset. At the level of gene selection, Golub et al. 
employ an algorithm that requires specification of the number of genes one hopes to 
select from the “training” set of samples. Accordingly, we used alternative statistical 
approaches20-23 with the same formal requirement for comparison. The resulting five sets 
of selected genes (“signatures”) are then used to classify independent “case” samples. 
The software GenePattern25 was used for data preprocessing. The preprocessed data was 
imported into the program R (The R Foundation for Statistical Computing, Version 2.1.1), 
in which all downstream analysis was performed (see Appendix Part B for the program 
codes). The gene sets selected from the training samples used by Golub were then 
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compared by calculating the kappa scores. κ-scores are reported at the level of gene-
selection on the “training” samples, and for sample classification and agreement with the 
clinical diagnosis of the “case” samples.  
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 t-test Golub SAM EBAM migs 
t-test 1.00 0.52 0.15 0.68 0.25 
Golub  1.00 0.54 0.40 0.31 
SAM   1.00 0.15 0.19 
EBAM    1.00 0.25 
migs     1.00 
 
Table 1: Kappa scores for agreement of “gene selection from training set” between the 
five methods  
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 t-test Golub SAM EBAM migs 
t-test 1.00 0.85 0.60 0.75 0.75 
Golub  1.00 0.65 0.79 0.68 
SAM   1.00 0.78 0.78 
EBAM    1.00 0.89 
migs     1.00 
 
Table 2: Kappa scores for agreement of “case sample clustering” between the five 
methods  
 
 
 t-test Golub SAM EBAM migs 
REAL 0.58 0.63 0.88 0.83 0.83 
 
Table 3: Kappa scores for agreement of “case sample clustering and clinical diagnosis” 
for the five methods 
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Appendix  
Part A 
Description of the data set and the statistical methodology  
Data set used for the analysis: The original training data set consisted of 38 bone marrow 
samples, containing 27 acute lymphoblastic leukemias (ALL) and 11 acute myeloid 
leukemias (AML)(1, 2). The independent (test) data set contained 20 ALL and 14 AML 
cases. The gene expression intensities were obtained from Affymetrix high-density 
oligonucleotide microarrays, containing probes for 6817 genes. In total, the data consists 
of 47 cases of ALL (38 B-Cell, 9 T-Cell) and 25 of AML.  
 
Golub’s GenePattern (1): The test employed by Golub et al is a variant of the diagonal 
linear discriminant analysis (DLDA). The genes are first sorted by their degree of 
correlation with the class distinction, which is a vector that represents which class (AML 
or ALL) each sample belongs to. Neighborhood analysis is then performed to establish 
whether the observed correlations are stronger than would be expected by chance. The 
top 50 genes most closely correlated with the AML-ALL distinction in the known 
“training” samples are then selected. The number 50 follows Golub’s original publication. 
The program code is available in Appendix Part B.  
 
Normalized mutual information-based gene selection (nMigs)(3): An entropy based 
algorithm named “normalized mutual information-based gene selction” calculates the 
relevance and redundancy of each gene for classification of “training” samples. The 50 
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most relevant genes with the least redundancy are selected. The program code is available 
in Appendix Part B. 
 
Student’s t-test(4): Standard deviation is calculated for the entire microarray’s gene  
expression level of all genes. For each gene, a mean expression value is obtained by 
taking the average of the repetitive expression signals. A 1-sample t-test is then 
performed for each gene to determine its deviation from 1, using the individual gene’s 
average expression and the entire microarray’s standard deviation in the calculation. The 
top 50 genes with the largest t-test values, indicative of the largest deviation from 1, are 
chosen. The program code is available in Appendix Part B. 
 
Significance Analysis of Microarrays (SAM)(5): A score is assigned to each gene on the 
basis of change in gene expression relative to the standard deviation of repeated 
measurements. For genes with scores greater than a threshold chosen by the investigator, 
SAM uses permutations of the repeated measurements to estimate the false discovery rate 
(FDR). A threshold value of 2.8 was set here. The program code is available in Appendix 
Part B. 
 
Empirical Bayes Analysis of Microarays (EBAM)(6): The EBAM algorithm used here is 
essentially a variation of the SAM method. The only difference lies in that EBAM uses a 
modified t-statistic in calculating the score. The program code is available in Appendix 
Part B. 
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Cohen’s kappa- score(7): Cohen’s kappa score gives a numerical rating of the degree to 
which interobserver variation occurs, in a situation where two or more independent 
observers or methods evaluate the same set of data.  
 
Kappa = (po - pe)/(1 - pe) 
where po = observed agreement  
pe = expected agreement  
 
Kappa scores of 0.01 to 0.20 are considered to describe “slight” agreement, while the 
quantification is “fair” for 0.21 to 0.40. For “moderate” and “substantial” agreement, the 
kappa scores range from 0.41 to 0.60 and 0.61 to 0.80 respectively. A kappa score of 0.81 
to 0.99 describes “almost perfect” agreement.    
 
Part B  
Program code 
#file: selgenes.r 
# R codes for select genes using  
#  (1) t-test (2) Prediciton Strength: PS (3) SAM (4) EBAM  
# author: Liu Xiaoxing, BII, A*STAR, Singapore 
# date: 05/08/2005 
 
#data file containing training data 
file.train <- 'golubtrain.txt' 
#read training data from the file 
data.train <- read.delim(file.train, header=F, row.names=1) 
#tumor types 
types.train <- data.train[1,] 
matrix.train <- data.train[-1,] 
rm(data.train) 
#number of genes to be selected 
ng <- 50 
 
# (1) gene selection by t-statistic 
 
  m1 <- apply(matrix.train[,types.train==1], 1, mean) 
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  m2 <- apply(matrix.train[,types.train==2], 1, mean) 
  v1 <- apply(matrix.train[,types.train==1], 1, var) 
  v2 <- apply(matrix.train[,types.train==2], 1, var) 
  s1 <- apply(matrix.train[,types.train==1], 1, sd) 
  s2 <- apply(matrix.train[,types.train==2], 1, sd) 
  n1 <- sum(types.train==1) 
  n2 <- sum(types.train==2) 
  scores.ttest <- abs(m1-m2) / sqrt((n1-1)*v1+(n2-1)*v2) 
 
index.ttest <- order(scores.ttest, decreasing=TRUE) 
sel.ttest <- index.ttest[1:ng] 
genes.ttest <- data.frame(sel.ttest, scores.ttest[sel.ttest]) 
row.names(genes.ttest) <- row.names(matrix.train)[sel.ttest] 
write.table(genes.ttest, file='ttest.txt', sep='\t', row.names=T, 
col.names=F) 
 
# (2) Golub's PS method 
scores.golub <- (m1-m2) / (s1+s2) 
index1.p <- order(scores.golub, decreasing=TRUE) 
index2.p <- order(scores.golub) 
sel.golub <- c(index1.p[1:(ng/2)], index2.p[1:(ng/2)]) 
genes.golub <- data.frame(sel.golub, scores.golub[sel.golub]) 
row.names(genes.golub) <- row.names(matrix.train)[sel.golub] 
write.table(genes.golub, file='golub.txt', sep='\t', row.names=T, 
col.names=F) 
 
# (3) & (4) 
#load library siggenes for SAM and EBAM 
library(siggenes) 
library(multtest) 
#prepare data format for SAM and EBAM 
cl <- factor(types.train-1, level=c(0,1)) 
cl <- as.vector(cl) 
cl <- as.numeric(cl) 
 
# Perform a SAM analysis  
sam.out <- sam(matrix.train,cl,rand=123) 
sam.sum <- summary(sam.out, 2.8, ll=FALSE) 
#sel.sam <- sam.sum@row.sig.genes[1:ng] 
genes.sam <- sam.sum@mat.sig[1:ng, 1:2] 
sel.sam <- genes.sam[,1] 
write.table(genes.sam, file='sam.txt', sep='\t', row.names=T, 
col.names=F) 
 
find.out <- find.a0(matrix.train,cl,rand=123) 
ebam.outa <- ebam(find.out) 
#sel.ebam <- ebam.outa$row.sig.genes[1:ng] 
genes.ebam <- ebam.outa$ebam.out[1:ng,1:2] 
sel.ebam <- genes.ebam[,1] 
write.table(genes.ebam, file='ebam.txt', sep='\t', row.names=T, 
col.names=F) 
 
#(5)random select genes twice 
sel.rand1 <- sample(c(1:nrow(matrix.train)), ng) 
genes.rand1 <- data.frame(sel.rand1) 
row.names(genes.rand1) <- row.names(matrix.train)[sel.rand1] 
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write.table(genes.rand1, file='rand1.txt', sep='\t', row.names=T, 
col.names=F) 
 
sel.rand2 <- sample(c(1:nrow(matrix.train)), ng) 
genes.rand2 <- data.frame(sel.rand2) 
row.names(genes.rand2) <- row.names(matrix.train)[sel.rand2] 
write.table(genes.rand2, file='rand2.txt', sep='\t', row.names=T, 
col.names=F) 
 
#(6) genes selected by migs (liu et al) 
#run program ./migs first to get the selected gene list 
sel.migs <- scan('allaml_wi_99_data_gene.txt') 
genes.migs <- data.frame(sel.migs) 
row.names(genes.migs) <- row.names(matrix.train)[sel.migs] 
write.table(genes.migs, file='migs.txt', sep='\t', row.names=T, 
col.names=F) 
 
#save all data 
save.image(file="selgenes.RData") 
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